Checking in on some stock volatility information, Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s 12 month volatility is 58.442400. The 6 month volatility is recorded at 45.310700, and the 3 month is spotted at 55.085300. When viewing stock volatility, investors may have to figure out a winning combination of risk-reward to help maximize profits. As with any trading strategy, it is smart to carefully consider risk and other market factors that may be in play when reviewing stock volatility levels.
Active investors are typically making every effort to maximize profit. Some investors may be applying price index ratios to help sort out trading ideas. Currently, Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s 6 month price index is 0.92516. The six month price index is calculated by dividing the current share price by the share price six months ago. A ratio greater than one indicates an increase in share price over the period. A ratio under one shows that there has been a price decrease over the time period.
Investors may also be interested in FCF or Free Cash Flow scores for Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Free cash flow represents the amount of cash that a firm has generated for shareholders after paying off expenses and investing in growth. FCF may be a good way to help gauge the financial health of a certain company. After a recent look, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has an FCF quality score of -2.820613. The free quality score helps estimate the stability of free cash flow. FCF quality is calculated as the 12 ltm cash flow per share over the average of the cash flow numbers. With this score, it is typically considered that the lower the ratio, the better. Currently, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has an FCF score of 0.195009. The FCF score is determined by merging free cash flow stability with free cash flow growth. In general, a higher FCF score value would represent high free cash flow growth.
Checking out the Value Composite score for Neurocrine Biosciences, Inc. (NASDAQ:NBIX), we notice that the stock has a current rank of 88. This is using a scale from 0 to 100 where a lower score would represent an undervalued company and a higher score would indicate an expensive or overvalued company. This rank was developed by James O’Shaughnessy in 2011. The score is derived from five different valuation ratios including price to book value, price to sales, EBITDA to Enterprise Vale, price to cash flow and price to earnings.
Traders might also be tracking the Piotroski Score or F-Score. The score was developed by Joseph Piotroski who devised a ranking scale from 0-9 to help determine the financial strength of a company. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) currently has a Piotroski Score of 3. To get to this score, Piotroski offered one point for every piece of criteria met out of the nine considered. In terms of profitability, one point was given if there was a positive return on assets in the current year, one point if operating cash flow was positive in the current year, one point for higher ROA in the current period compared to ROA for the previous year, and one point for cash flow from operations greater than ROA. In terms of leverage and liquidity, one point was given for a lower ratio of long term debt in the current period compared to the previous year, one point was given for higher current ratio compared to the previous year, and one point if no new shares were issued in the last year. In terms of operating efficiency, one point was given for higher gross margin compared to the previous year, and one point was given for a higher asset turnover ratio compared to the previous year. In general, a stock with a score of 8 or 9 would be considered strong while a stock with a score from 0-2 would be considered weak.